JP5081630B2 - ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法 - Google Patents

ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法 Download PDF

Info

Publication number
JP5081630B2
JP5081630B2 JP2007550488A JP2007550488A JP5081630B2 JP 5081630 B2 JP5081630 B2 JP 5081630B2 JP 2007550488 A JP2007550488 A JP 2007550488A JP 2007550488 A JP2007550488 A JP 2007550488A JP 5081630 B2 JP5081630 B2 JP 5081630B2
Authority
JP
Japan
Prior art keywords
irna agent
rsv
composition
irna
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007550488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526876A (ja
JP2008526876A5 (https=
Inventor
マイヤーズ、レイチャル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Pharmaceuticals Inc
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of JP2008526876A publication Critical patent/JP2008526876A/ja
Publication of JP2008526876A5 publication Critical patent/JP2008526876A5/ja
Application granted granted Critical
Publication of JP5081630B2 publication Critical patent/JP5081630B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007550488A 2005-01-07 2006-01-06 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法 Expired - Fee Related JP5081630B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64236405P 2005-01-07 2005-01-07
US60/642,364 2005-01-07
US65982805P 2005-03-09 2005-03-09
US60/659,828 2005-03-09
PCT/US2006/000425 WO2006074346A2 (en) 2005-01-07 2006-01-06 RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011220918A Division JP5814728B2 (ja) 2005-01-07 2011-10-05 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法

Publications (3)

Publication Number Publication Date
JP2008526876A JP2008526876A (ja) 2008-07-24
JP2008526876A5 JP2008526876A5 (https=) 2009-02-19
JP5081630B2 true JP5081630B2 (ja) 2012-11-28

Family

ID=36648197

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007550488A Expired - Fee Related JP5081630B2 (ja) 2005-01-07 2006-01-06 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法
JP2011220918A Expired - Fee Related JP5814728B2 (ja) 2005-01-07 2011-10-05 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法
JP2014113800A Pending JP2014156491A (ja) 2005-01-07 2014-06-02 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011220918A Expired - Fee Related JP5814728B2 (ja) 2005-01-07 2011-10-05 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法
JP2014113800A Pending JP2014156491A (ja) 2005-01-07 2014-06-02 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法

Country Status (14)

Country Link
US (8) US7507809B2 (https=)
EP (4) EP2230304B1 (https=)
JP (3) JP5081630B2 (https=)
KR (1) KR101169668B1 (https=)
CN (2) CN102600480B (https=)
AT (1) ATE551421T1 (https=)
AU (2) AU2006203934B2 (https=)
CA (1) CA2594334A1 (https=)
DK (1) DK2230304T3 (https=)
EA (3) EA017847B1 (https=)
ES (1) ES2385811T3 (https=)
IL (2) IL184162A (https=)
NZ (1) NZ556097A (https=)
WO (1) WO2006074346A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) * 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US7592322B2 (en) * 2004-10-22 2009-09-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
NZ556097A (en) * 2005-01-07 2009-12-24 Alnylam Pharmaceuticals Inc Rnai modulation of RSV and therapeutic uses thereof
US20100196509A1 (en) 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
DK2308514T3 (da) 2007-03-23 2013-09-02 To Bbb Holding B V Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
US20100215588A1 (en) * 2007-04-26 2010-08-26 Rami Skaliter Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system
ES2428009T3 (es) 2007-07-05 2013-11-05 Novartis Ag ARNds para tratar infecciones virales
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
WO2009055445A2 (en) * 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2008334948B2 (en) * 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
US20100168205A1 (en) * 2008-10-23 2010-07-01 Alnylam Pharmaceuticals, Inc. Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules
ES2804764T3 (es) 2009-06-01 2021-02-09 Halo Bio Rnai Therapeutics Inc Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos
EP2495323A4 (en) * 2009-10-30 2014-04-30 Daiichi Sankyo Co Ltd MODIFIED DOUBLE-STRENGTH POLYNUCLEOTIDE
JP5911805B2 (ja) 2009-11-20 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ）
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2012027206A1 (en) * 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc Methods of Treatment
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
HUE039734T2 (hu) 2012-05-29 2019-01-28 Parion Sciences Inc Nátriumcsatorna-blokkoló aktivitású, dendrimerszerû amino-amid-származékok száraz szem és más nyálkahártya-megbetegedések kezelésére
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
KR20150137350A (ko) * 2014-05-29 2015-12-09 삼성전자주식회사 화상형성장치 및 화상형성장치의 스캔 방법
JP2018525037A (ja) 2015-08-24 2018-09-06 ハロー−バイオ・アールエヌエーアイ・セラピューティックス、インコーポレイテッド 遺伝子発現の調節のためのポリヌクレオチドナノ粒子及びその使用
CN105693557A (zh) * 2016-01-04 2016-06-22 湖北卓熙氟化股份有限公司 一种氟化氢尿素及其制备方法
JP2018012236A (ja) * 2016-07-20 2018-01-25 株式会社東芝 印刷システム
CN108689886B (zh) * 2018-06-22 2021-06-15 湖北卓熙氟化股份有限公司 一种氟化氢尿素的制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
HU205839B (en) * 1987-11-18 1992-07-28 Chinoin Gyogyszer Es Vegyeszet Synergetic artropodicide composition containining pirethroides and phosphate-esters as active components
CA2183992A1 (en) * 1994-02-23 1995-08-31 Dan T. Stinchcomb Method and reagent for inhibiting the expression of disease related genes
US5693532A (en) * 1994-11-04 1997-12-02 Ribozyme Pharmaceuticals, Inc. Respiratory syncytial virus ribozymes
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
AU6848396A (en) * 1995-10-17 1997-05-07 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
WO1997029757A1 (en) * 1996-02-15 1997-08-21 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
WO1998012312A1 (en) 1996-09-18 1998-03-26 Vanderbilt University Antisense gene therapy for rna viruses
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20060287267A1 (en) * 2001-05-18 2006-12-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
WO2003008628A2 (en) * 2001-07-20 2003-01-30 Ribozyme Pharmacuticals, Inc. Enzymatic nucleic acid peptide conjugates
US6881835B2 (en) * 2002-01-04 2005-04-19 Dr. Chip Biotechnology Inc. Detection of respiratory viruses
WO2003062258A1 (en) * 2002-01-22 2003-07-31 The Cleveland Clinic Foundation Rnase l activator-antisense complexes
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
WO2004042002A2 (en) * 2002-08-05 2004-05-21 University Of Massachusetts Compounds for modulating rna interference
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
MXPA05003287A (es) * 2002-09-28 2005-07-05 Massachusetts Inst Technology Influenza terapeutica.
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
WO2004080406A2 (en) 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Therapeutic compositions
AU2004227414A1 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals iRNA conjugates
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
JP4991288B2 (ja) 2003-04-17 2012-08-01 アルナイラム ファーマシューティカルズ， インコーポレイテッド 二本鎖ｉＲＮＡ剤、および二本鎖ｉＲＮＡ剤の対合の安定性を調節する方法。
TW572579U (en) * 2003-05-12 2004-01-11 Enermax Technology Corp Power supply still capable of dissipating heat after powering off a computer
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
EP1713819A4 (en) * 2004-02-05 2007-11-14 Intradigm Corp METHOD AND COMPOSITIONS FOR COMBINING RNAI THERAPEUTICS
WO2005097817A2 (en) * 2004-04-05 2005-10-20 Alnylam Pharmaceuticals, Inc. Process and reagents for oligonucleotide synthesis and purification
WO2006085987A2 (en) * 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
US7592322B2 (en) * 2004-10-22 2009-09-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
CA2586250A1 (en) * 2004-11-05 2006-11-16 Intradigm Corporation Compositions for treating respiratory viral infections and their use
NZ556097A (en) 2005-01-07 2009-12-24 Alnylam Pharmaceuticals Inc Rnai modulation of RSV and therapeutic uses thereof
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
US20070213293A1 (en) 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
US7718629B2 (en) 2006-03-31 2010-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 gene
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
WO2009055445A2 (en) 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2008334948B2 (en) 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
US20100168205A1 (en) 2008-10-23 2010-07-01 Alnylam Pharmaceuticals, Inc. Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules

Also Published As

Publication number Publication date
US20060166921A1 (en) 2006-07-27
JP2008526876A (ja) 2008-07-24
AU2010224450A1 (en) 2010-10-21
KR101169668B1 (ko) 2012-08-07
CN102600480A (zh) 2012-07-25
ATE551421T1 (de) 2012-04-15
EP2628799A3 (en) 2013-08-28
KR20070110019A (ko) 2007-11-15
CN102600480B (zh) 2015-07-22
US20060258608A1 (en) 2006-11-16
US8859750B2 (en) 2014-10-14
ES2385811T3 (es) 2012-08-01
NZ556097A (en) 2009-12-24
EP2230304B1 (en) 2012-03-28
US20130030037A1 (en) 2013-01-31
DK2230304T3 (da) 2012-07-16
WO2006074346A3 (en) 2007-07-05
EA012573B1 (ru) 2009-10-30
JP5814728B2 (ja) 2015-11-17
CN101119734A (zh) 2008-02-06
AU2010224450B2 (en) 2014-04-10
WO2006074346A2 (en) 2006-07-13
AU2006203934A1 (en) 2006-07-13
US20090240043A1 (en) 2009-09-24
EP1833490A2 (en) 2007-09-19
US7507809B2 (en) 2009-03-24
EP2487243A3 (en) 2013-08-28
CA2594334A1 (en) 2006-07-13
EP1833490A4 (en) 2010-09-15
EA017847B1 (ru) 2013-03-29
IL184162A0 (en) 2007-10-31
US20090233984A1 (en) 2009-09-17
IL184162A (en) 2013-07-31
EP2487243A2 (en) 2012-08-15
US7517865B2 (en) 2009-04-14
US8158773B2 (en) 2012-04-17
EP2628799A2 (en) 2013-08-21
US7981869B2 (en) 2011-07-19
US20150011612A1 (en) 2015-01-08
IL217332A (en) 2013-07-31
AU2006203934B2 (en) 2010-09-09
EA200701450A1 (ru) 2008-02-28
US20130005791A1 (en) 2013-01-03
US8263572B2 (en) 2012-09-11
EA200900681A1 (ru) 2009-12-30
US20110313023A1 (en) 2011-12-22
EA201201356A1 (ru) 2013-07-30
CN101119734B (zh) 2012-05-09
JP2014156491A (ja) 2014-08-28
JP2012006980A (ja) 2012-01-12
IL217332A0 (en) 2012-02-29
EP2230304A1 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
JP5081630B2 (ja) ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法
KR101193825B1 (ko) ＲＳＶ, ＰＩＶ 및 기타 호흡기 바이러스의 ＲＮＡｉ 조절및 이의 용도
HK1176083A (en) Rnai modulation of rsv and therapeutic uses thereof
HK1144102A1 (en) Rnai modulation of rsv and therapeutic uses thereof
HK1144102B (en) Rnai modulation of rsv and therapeutic uses thereof
HK1114308B (en) Rnai modulation of rsv, piv and other respiratory viruses and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081008

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081008

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120711

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120814

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120903

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150907

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees